Medication Risk Management for Long-Term Care
Pharmacogenomics is the study of drug-genome interactions and their clinical implications. This form of precision medicine looks for genetic markers that indicate how a resident might respond to a drug.
Over 2 million prescriptions in the U.S. result in an adverse reaction because response rates vary.
Pharmacogenomic risk assessments and testing can help facilities and providers identify, monitor, and manage potential issues associated with resident medications.
Benefits to Skilled Nursing Facilities
- Fewer adverse drug events
- Increased cost savings
- Better outcomes
Today, there are more than 450 medications whose use is improved by understanding a resident’s genetic makeup based on FDA drug labels.
A simple DNA test can reveal how a resident’s body metabolizes a specific drug compound to inform the care team so it can customize treatment and calculate optimal dosing.
PharMerica consultant pharmacists incorporate the DNA test results into their evaluation of all available clinical evidence to establish whether the genetic information can be used in determining therapeutic treatment, one of many patient aspects that are considered during the medication regimen review.
Most insurance companies utilized by long-stay residents, including Medicare Part D and Medicaid plans, cover the cost of this testing for eligible members.
PharMerica has partnered with SinguLab®, a nationwide provider of precision medicine solutions, to offer pharmacogenomic risk assessments and testing to help facilities and providers identify, monitor, and manage potential issues associated with resident medications. Contact your account manager for more information.